ISTANBUL, Aug. 06, 2026 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), today announces its unaudited financial results for the second quarter ended June 30, 2026. Restatement of financial information: Pursuant to the International Accounting Standard 29, Financial Reporting in Hyperinflationary Economies (“IAS 29”), the financial statements of entities whose functional currency is that of a hyperinflationary economy must be adjusted for the effects of changes in a general price index. Turkish companies reporting under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), including the Company, have been required to apply...

6 August 2026 The EIB submits SEC Form 18-K/A Amendment No. 4 The European Investment Bank (EIB) has submitted SEC Form 18-K/A Amendment No. 4. To view the document, please go to: EDGAR Filing Documents for 0000950157-26-000854 The 18-K/A has also been posted on the EIB website:Amendment to the Annual Report 2025 (Form 18-K/A Amendment No.4) ENDS

Press Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on August 13, 2026, at 2:00 pm CEST (8:00 am ET) following the announcement of financial results for the second quarter / first six months of 2026. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session. To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI5e8456a3bc14478c80422f79bbd72ef6.The...

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 HighlightsGenmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival Genmab revenue increased 25% compared to the first six months of 2025, to $2,051 million Genmab 2026 financial guidance updated“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and patient populations. At the same time, new data further support the development of Rina-S® (rinatabart sesutecan) in combination...

BALTIMORE, Aug. 06, 2026 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for second quarter 2026.(1) Second Quarter 2026 Highlights(1)Billings for second quarter 2026 totaled $91.2 million, representing a 57% year-over-year increase compared to second quarter 2025, and the highest quarterly Billings since 2023.Cash from Operating Activities (“CFFO”) was $22.4 million in the second quarter 2026, an increase of $4.6 million or 25.7% compared to the second quarter 2025, primarily driven by higher Billings and  movements in working capital.Total Net Revenue was $75.8 million in the second quarter 2026(2)Net...

TEJON RANCH, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate, land and agribusiness company, today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsNet income attributable to common stockholders increased by $4.3 million to $2.6 million ($0.10/share basic and diluted), compared to a loss of $1.7 million, ($0.06/share) in the second quarter of 2025. Revenues and other income, including equity in earnings of unconsolidated joint ventures increased by $6.3 million to $17.4 million, compared to $11.1 million, in the second quarter of 2025, while overall results also benefited from disciplined cost management, with year-to-date corporate expenses of $4.7 million compared...

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology...

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The Company expects to complete...

Revenue Growth of 20%, Positive Operating Income, and Increased Dairy RNG ProductionRevenues of $62.7 million, an increase of $10.5 million or 20% over the second quarter of 2025, with growth across California Ethanol and Dairy RNG segments and $8.6 million of Section 45Z tax credits Operating income improved by $16.4 million compared to the second quarter of 2025 Net loss of $9.4 million improved by $14.0 million compared to the second quarter of 2025 Adjusted EBITDA of $9.7 million improved by $15.5 million compared to the second quarter of 2025 Aemetis Biogas RNG sales volume grew 38% to 146,900 MMBtu, compared with 106,400 MMBtu in the second quarter of 2025 Ten digester cleanup skids have been received, and two biogas dairy digesters are expected to be commissioned in the third quarter of 2026CUPERTINO, Calif., Aug. 06, 2026...

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026 Appointed new Chief Medical Officer, Chief Business Officer, and Board Member to strengthen senior leadership and guide the Company through registrational studies and commercialization readinessNORWOOD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 second quarter ended June 30, 2026.  “We’ve...